CN110177577A - Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 - Google Patents

Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 Download PDF

Info

Publication number
CN110177577A
CN110177577A CN201780052351.9A CN201780052351A CN110177577A CN 110177577 A CN110177577 A CN 110177577A CN 201780052351 A CN201780052351 A CN 201780052351A CN 110177577 A CN110177577 A CN 110177577A
Authority
CN
China
Prior art keywords
sfasl
raav
subject
mice
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780052351.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·马沙克-罗斯坦
M·格雷戈里-克桑德
B·克桑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
University of Massachusetts Amherst
Original Assignee
Brigham and Womens Hospital Inc
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, University of Massachusetts Amherst filed Critical Brigham and Womens Hospital Inc
Publication of CN110177577A publication Critical patent/CN110177577A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780052351.9A 2016-07-05 2017-07-05 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 Pending CN110177577A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358541P 2016-07-05 2016-07-05
US62/358,541 2016-07-05
US201762511629P 2017-05-26 2017-05-26
US62/511,629 2017-05-26
PCT/US2017/040735 WO2018009553A1 (en) 2016-07-05 2017-07-05 Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma

Publications (1)

Publication Number Publication Date
CN110177577A true CN110177577A (zh) 2019-08-27

Family

ID=60912274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780052351.9A Pending CN110177577A (zh) 2016-07-05 2017-07-05 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法

Country Status (7)

Country Link
US (2) US20190240353A1 (enExample)
EP (1) EP3481433B1 (enExample)
JP (2) JP7493334B2 (enExample)
KR (1) KR20190096329A (enExample)
CN (1) CN110177577A (enExample)
MX (1) MX2019000221A (enExample)
WO (1) WO2018009553A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6884755B2 (ja) 2015-05-01 2021-06-09 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
US10862211B2 (en) * 2018-08-21 2020-12-08 Htc Corporation Integrated antenna structure
US10818758B2 (en) 2018-11-16 2020-10-27 Asm Ip Holding B.V. Methods for forming a metal silicate film on a substrate in a reaction chamber and related semiconductor device structures
WO2023048529A1 (ko) * 2021-09-27 2023-03-30 (주) 씨드모젠 Aav2-f11 단백질을 유효성분으로 포함하는 녹내장 예방 또는 치료용 조성물
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
TW202346600A (zh) * 2022-03-30 2023-12-01 高等教育聯邦系統 匹茲堡大學 用於將核酸遞送至視網膜神經節細胞和/或視網膜色素上皮細胞的腺相關病毒載體

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192823A1 (en) * 2001-01-05 2002-12-19 Bartlett Jeffrey S. AAV2 vectors and methods
US20040126859A1 (en) * 1996-11-13 2004-07-01 Keting Chu Mutant forms of Fas ligand and uses thereof
US20140024598A1 (en) * 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
WO2015044462A1 (en) * 2013-09-30 2015-04-02 Sanofi Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
ATE317916T1 (de) 2001-11-13 2006-03-15 Univ Pennsylvania Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode
GB0820262D0 (en) * 2008-11-05 2008-12-10 Tmo Renewables Ltd Microorganisms
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2586793A1 (en) * 2011-10-27 2013-05-01 Centre National de la Recherche Scientifique Chimeric molecule involving oligomerized FasL extracellular domain
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
CN110885854A (zh) * 2013-03-15 2020-03-17 北卡罗来纳-查佩尔山大学 双重聚糖结合aav载体的方法和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126859A1 (en) * 1996-11-13 2004-07-01 Keting Chu Mutant forms of Fas ligand and uses thereof
US20020192823A1 (en) * 2001-01-05 2002-12-19 Bartlett Jeffrey S. AAV2 vectors and methods
US20140024598A1 (en) * 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
WO2015044462A1 (en) * 2013-09-30 2015-04-02 Sanofi Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GREGORY M.S.等: "Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death", 《PLOS ONE》 *
GREGORY M.S.等: "Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death", 《PLOS ONE》, vol. 6, no. 3, 29 March 2011 (2011-03-29), pages 1 - 13 *
KRISHNAN A.等: "Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of glaucoma", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 *
KRISHNAN A.等: "Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of glaucoma", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》, vol. 56, 30 June 2015 (2015-06-30) *
KRISHNAN A.等: "Gene therapy treatment with AAV-solubleFas ligand protects retinal ganglion cellsduring development of Glaucoma", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 56 *
QIUHONG LI等: "Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential", 《MOLECULAR VISION》 *
QIUHONG LI等: "Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential", 《MOLECULAR VISION》, vol. 14, 24 September 2008 (2008-09-24), pages 1760 - 1769, XP055657882 *

Also Published As

Publication number Publication date
WO2018009553A1 (en) 2018-01-11
EP3481433B1 (en) 2024-07-03
JP2019520405A (ja) 2019-07-18
JP7493334B2 (ja) 2024-05-31
MX2019000221A (es) 2020-02-07
US20250001015A1 (en) 2025-01-02
CA3029864A1 (en) 2018-01-11
JP2022084594A (ja) 2022-06-07
EP3481433A4 (en) 2020-02-26
KR20190096329A (ko) 2019-08-19
US20190240353A1 (en) 2019-08-08
EP3481433A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
AU2020201190B2 (en) Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
CN110177577A (zh) Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
KR20220066914A (ko) 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료
JP7535332B2 (ja) ミニ遺伝子療法
CN112522271B (zh) 一种sgRNA及其应用
CN117715660A (zh) 右心室致心律失常性心肌病的基因治疗组合物和治疗
CN109055428A (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN115335529A (zh) 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
JP2024538076A (ja) ステレオシリンプロモーター及びその使用
CN112342228B (zh) 表达抗vegf融合蛋白的aav病毒载体及其应用
AU2021254852B2 (en) Gene therapy for Bardet-Biedl syndrome
CN111793632A (zh) 变异的Gsdmd-C核酸片段，包含所述核酸片段的载体及应用
JP2021522791A (ja) Ａａｖ適合性ラミニン−リンカー重合タンパク質
CN112301058B (zh) 一种重组腺相关病毒载体及其制备方法与应用
US6652850B1 (en) Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
CN112301057B (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN115052634B (zh) 前庭支持细胞启动子和其用途
TWI902721B (zh) 前庭支持細胞啟動子及其用途
CN114686521A (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN116829722A (zh) 用于递送kh902(康柏西普)的腺相关病毒及其用途
RU2833225C2 (ru) Аденоассоциированный вирусный вектор, состоящий из белков капсида рнр.в, нуклеиновой кислоты, кодирующей белок smn, и его применение
WO2024123200A1 (en) A nucleic acid construct for use in the gene therapy for glaucoma
CA3029864C (en) Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
WO2024238890A1 (en) Compositions and methods for treating gjb2-related hearing loss

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190827